European Medicines Agency
EU centralised medicines data from EMA's published data files: authorised medicines (EPAR pages), CHMP and CVMP opinions and withdrawn applications, applications under evaluation, EU orphan designations, EPAR and product documents, and EMA-assessed supply shortages, with EMA attribution on every result.
6 Firecrawl tools use European Medicines AgencyTry European Medicines Agency now.
Choose an example or ask your own question.
const result = await firecrawl.scrape({
alexandria: {
provider: "ema-europa-eu",
capability: "records/applications",
options: {
limit: 3,
month: "2026-10",
},
},
});This is a sample shape. Press Run to see live data from European Medicines Agency.
{
"license": {
"attribution": "Source: European Medicines Agency (EMA), https://www.ema.europa.eu. Reproduced under EMA's legal notice, which requires EMA to be acknowledged as the source: https://www.ema.europa.eu/en/about-us/about-website/legal-notice",
"name": "EMA legal notice",
"url": "https://www.ema.europa.eu/en/about-us/about-website/legal-notice"
},
"month": "2026-10",
"next_cursor": "3",
"observed_at_ms": 1793381388392,
"records": [
{
"accelerated_assessment": false,
"ema_product_number": "EMEA/H/C/006741",
"generic_hybrid_or_biosimilar": true,
"inn": "Abatacept",
"open": false,
"orphan": false,
"prime": false,
"restarted_after_questions": null,
"reverted_to_standard_timetable": null,
"start_of_evaluation": "2026-06-18",
"substance_type": "Biologicals",
"therapeutic_area": null
},
{
"accelerated_assessment": false,
"ema_product_number": "EMEA/H/C/007032",
"generic_hybrid_or_biosimilar": true,
"inn": "Abatacept",
"open": false,
"orphan": false,
"prime": false,
"restarted_after_questions": null,
"reverted_to_standard_timetable": null,
"start_of_evaluation": "2026-10-01",
"substance_type": "Biologicals",
"therapeutic_area": null
},
{
"accelerated_assessment": false,
"ema_product_number": "EMEA/H/C/006857",
"generic_hybrid_or_biosimilar": false,
"inn": "Aceclidine",
"open": false,
"orphan": false,
"prime": false,
"restarted_after_questions": null,
"reverted_to_standard_timetable": null,
"start_of_evaluation": "2026-03-26",
"substance_type": "Chemicals",
"therapeutic_area": null
}
],
"source_updated_at": "2026-10-05",
"source_url": "https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-october-2026_en.xlsx",
"total_matching": 92,
"withheld_fields": [
"indication_summary"
]
}Source: European Medicines Agency (EMA), https://www.ema.europa.eu. Reproduced under EMA's legal notice, which requires EMA to be acknowledged as the source. (https://www.ema.europa.eu/en/about-us/about-website/legal-notice)
Firecrawl tools
6Ready-made Firecrawl tools that call European Medicines Agency.
Benchmarks
Life sciences benchmarksQuality, speed and cost, last 24 hours, across every agent call to European Medicines Agency through Alexandria.
- Quality
- 97.5%
- Calls answered without a tool error
- Speed
- 3.4 s
- 95% of successful calls finish faster
- Cost
- 5 credits
- Firecrawl credits per call
- Calls
- 159
- Last 24 hours, every Alexandria user
| Tool | Quality | Speed | Calls |
|---|---|---|---|
| Medicines | 100% | 3.4 s | 42 |
| Orphan designations | 100% | 3.4 s | 30 |
| Opinions | 100% | 2.0 s | 27 |
| Applications | 100% | 4.8 s | 23 |
| Documents | 80% | 3.4 s | 20 |